Table 2.

Model-based means and standard errors for baseline pre-capsaicin dermal blood flow (DBF) (arbitrary units) and P-values assessing treatment effect (n= 12)

	Capsaicin dose*
Treatment	300 µg per 20 µl	1000 µg per 20 µl
Telcagepant 300 mg	0.453 (0.0232)	0.424 (0.0210)
Telcagepant 800 mg	0.450 (0.0228)	0.434 (0.0214)
Placebo	0.449 (0.0228)	0.414 (0.0210)
P-value†	0.99	0.73

^*Baseline DBF scans were performed immediately before capsaicin application, at 0.5 h and 3.5 h after telcagepant or placebo.

^†P-value from model including terms for period, site, arm and treatment with subject as a random effect. Separate model used for 300 and 1000 µg per 20 µl capsaicin doses.